Business Context and Reporting Period
Company: Longeveron Inc. (LGVN)
Filing Type: Form 8-K (Current Report)
Date of Report: March 3, 2021
Event: Entry into a Second Amendment to the Exclusive License Agreement with the University of Miami (UM) and issuance of unregistered equity securities.
Key Financial Metrics and Transaction Details
This filing reports a specific contractual amendment rather than periodic financial performance. Key financial terms include:
- License Fee Increase: Additional fee of $100,000 payable to UM to defray patent costs.
- $70,000 due within 30 days of the effective date.
- Remaining $30,000 payable in three equal installments of $7,500 on the 2nd, 3rd, and 5th year anniversaries.
- Equity Issuance: Issuance of 110,387 unregistered shares of Class A common stock to UM.
- Revised Milestone Payments:
- Phase II completion: $0 (previously payable).
- Phase III completion: $500,000.
- Regulatory Approval (NDA/BLA): $500,000.
- First Sale post-approval: $500,000.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity as this is a current report on a specific event, not a periodic financial statement.
Material Changes Versus Prior Period
The filing details material modifications to the 2014/2017 Exclusive License Agreement:
- Payment Structure: Elimination of the Phase II clinical trial milestone payment.
- Technology Scope: Expansion of licensed technology to include:
- BB-IND 15679 (CRTUS IND) regarding Allogenic Human Mesenchymal Stem Cells for Aging Frailty.
- BB-IND 16045 (HLHS IND) regarding Allogeneic hMSC Injection for Hypoplastic Left Heart Syndrome.
- Specific patent applications (PCT/US2015/060624) and invention disclosures (UMP-106).
- Exclusive Options: Grant of a two-year exclusive option (extendable) for:
- HLHS IND with ckit+ cells.
- UMP-438 regarding responsiveness to cell therapy in Dilated Cardiomyopathy.
Guidance, Outlook, and Risks
Management Commentary: The Company executed the amendment to secure additional technology rights and clarify milestone obligations. A press release regarding this agreement was issued on March 10, 2021.
Risks and Contingencies:
- Equity Registration: The 110,387 shares issued to UM are unregistered and may not be offered or sold in the U.S. absent registration or an applicable exemption (Section 4(a)(2)).
- Future Obligations: The Company is contingent on future clinical trial completions and regulatory approvals to trigger the $1.5 million in potential milestone payments.
- Patent Costs: The Company and UM must agree on decisions related to ongoing patent costs if exclusive options are exercised.
Investor Verification Checklist
- Verify the dilution impact of the 110,387 unregistered shares issued to the University of Miami.
- Confirm the cash outflow schedule for the $100,000 license fee increase ($70k immediate, $30k deferred).
- Review the status of the CRTUS IND (Aging Frailty) and HLHS IND (Hypoplastic Left Heart Syndrome) clinical trials to assess the likelihood of triggering the new $500k milestones.
- Check for any subsequent filings regarding the exercise of the exclusive options for the HLHS IND with ckit+ cells or UMP-438.